A Case Series of Eight Mucormycosis Patients during SARS-CoV-2 –Pandemic

Journal of Pharmaceutical Care, Journal Year: 2024, Volume and Issue: unknown

Published: July 2, 2024

The outbreak of opportunistic fungal infections such as mucormycosis has been a critical issue following coronavirus disease 19 (COVID-19). Mucormycosis is happened by the group Mucorales and commonly affects immunocompromised patients. To date, COVID-19-associated (CAM) being reported in several countries. It should be noted that CAM started patients approximately within two to three weeks after onset COVID-19. However, here, one case, symptoms appeared just week. In with due this enigmatic infection, sinuses were most affected, followed orbit, nose, finally brain. All cases received glucocorticoids part viral therapy. Diabetes mellitus (DM) was all but case which COVID-19 detected, without complications, may sole predisposing agent. Therefore, manuscript, we eight COVID-19-induced mucormycosis. Although experienced evacuation right eye, others discharge promising outcomes receiving surgical debridement proper anti-fungal treatment including, amphotericin B, caspofungin, posaconazole.

Language: Английский

Comprehensive Management of Rhino‐Orbito‐Cerebral Mucormycosis Post‐COVID‐19: A Case Report

Clinical Case Reports, Journal Year: 2024, Volume and Issue: 12(12)

Published: Dec. 1, 2024

ABSTRACT Post‐COVID‐19 mucormycosis, particularly the rhino‐orbital‐cerebral form, can be life‐threatening. This case highlights importance of maintaining high clinical suspicion, especially in patients with recent COVID‐19 history. Prompt diagnosis, aggressive surgical debridement, and antifungal therapy are crucial for successful management, even without traditional risk factors.

Language: Английский